Wonsart 40 Tablet contains Telmisartan 40 mg, an angiotensin II receptor blocker (ARB) primarily indicated for the management of hypertension. By selectively inhibiting the binding of angiotensin II to the AT1 receptor, Telmisartan effectively reduces vasoconstriction and aldosterone secretion, leading to decreased peripheral vascular resistance and lowered blood pressure. This mechanism helps in preventing complications associated with hypertension such as stroke, myocardial infarction, and renal impairment. Wonsart 40 is also utilized in reducing cardiovascular risk in patients with established atherosclerotic cardiovascular disease or type 2 diabetes mellitus with target organ damage. The medication is generally well-tolerated, with common adverse effects including dizziness, headache, and fatigue. It is contraindicated in patients with hypersensitivity to Telmisartan or any component of the formulation, and caution is advised in patients with renal or hepatic impairment. Wonsart 40 should not be used during pregnancy due to the risk of fetal toxicity. Dosage should be individualized based on patient response, with regular monitoring of blood pressure and renal function recommended during therapy. Wonsart 40 offers an effective and convenient option for long-term management of hypertension and cardiovascular risk reduction.